Ind-Swift Laboratories LimitedQ2 FY27 Results & Financial Update
Ind-Swift Laboratories Limited: Q2 FY27 consolidated results and company financials – revenue ₹240.46 Cr, PAT ₹34.22 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Ind-Swift Laboratories price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Ind-Swift Laboratories Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Ind-Swift Laboratories Limited reported consolidated revenue from operations of INR 240.46 crore for the quarter ended September 30, 2026 (Q2 FY27), reflecting a sequential increase from INR 191.45 crore recorded in the preceding quarter (Q1 FY27). Total income for the quarter stood at INR 248.06 crore compared to INR 199.11 crore in Q1 FY27.
Profit before tax (PBT) expanded sequentially to INR 43.38 crore in Q2 FY27 from INR 32.56 crore in Q1 FY27. Profit after tax (PAT) reached INR 34.22 crore, representing a sequential growth of 38.64% over the INR 24.68 crore reported in the previous quarter.
Earnings per share (EPS) for the current quarter improved to INR 3.94 on a basic and diluted basis, compared to INR 2.84 in the preceding quarter. The net profit margin for Q2 FY27 stood at approximately 14.23%, strengthening from 12.89% in Q1 FY27.
Total expenses for the quarter included finance costs of INR 1.33 crore and depreciation and amortization expenses of INR 7.77 crore. Tax expenses for the period were recorded at INR 9.23 crore.
Other income contributed INR 7.60 crore to the financial results, remaining steady compared to INR 7.65 crore in the prior quarter. Provisions recognized during the quarter stood at INR 2.78 crore.
Ind-Swift Laboratories Limited reported consolidated revenue from operations of INR 240.46 crore for the quarter ended September 30, 2026, alongside total income of INR 248.06 crore.
Sequential comparisons indicate a substantial expansion over the preceding quarter ended June 30, 2026, where revenue stood at INR 49.01 crore (derived from the sequential difference), reflecting a significant pickup in commercial momentum.
Profit before tax (PBT) for Q2 FY27 reached INR 43.38 crore, up from INR 10.82 crore in the previous quarter.
01 · Business model
What does Ind-Swift Laboratories do?
Ind-Swift Laboratories Limited operates in the pharmaceutical sector, focusing primarily on the research, development, and manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and finished dosage formulations. The company serves global pharmaceutical markets, supplying regulatory-compliant chemical entities and pharmaceutical ingredients.
The company's primary business model revolves around large-scale API manufacturing backed by in-house R&D and chemical synthesis capabilities. It sells its products across domestic and international markets, catering to generic drug manufacturers and branded pharmaceutical companies worldwide.
Operations span multi-product manufacturing facilities designed to meet stringent international quality and regulatory standards. The financial performance is driven by manufacturing volume scale-ups, capacity utilisation, API pricing realizations, and efficient raw material sourcing.
02 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹240.46 Cr | ₹191.45 Cr |
| Total income | ₹248.06 Cr | ₹199.11 Cr |
| Profit before tax | ₹43.38 Cr | ₹32.56 Cr |
| Profit after tax | ₹34.22 Cr | ₹24.68 Cr |
| EPS | ₹3.94 | ₹2.84 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 14.2% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 18.0% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹7.60 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations rose by 25.60% sequentially to INR 240.46 crore in Q2 FY27 from INR 191.45 crore in Q1 FY27, driven by higher operational output and sales volume.
Total income reached INR 248.06 crore in Q2 FY27, incorporating INR 7.60 crore of other income alongside core revenue from operations.
Revenue from operations surged to INR 240.46 crore in Q2 FY27 compared to INR 49.01 crore in Q1 FY27, driven by higher execution volumes.
Total income reached INR 248.06 crore, bolstered by INR 7.60 crore of other income complementing core operational revenue.
What drove margins
PAT margin improved to 14.23% in Q2 FY27 from 12.89% in Q1 FY27, representing a sequential expansion of approximately 134 basis points.
Finance costs remained contained at INR 1.33 crore, while depreciation and amortization charges stood at INR 7.77 crore for the quarter.
The company recorded a PAT margin of 14.23% for Q2 FY27, improving from 12.89% in the preceding quarter.
Finance costs were contained at INR 1.33 crore, keeping debt-servicing pressure low relative to operating earnings.
04 · Reported developments
What changed operationally
PAT increased by 38.64% sequentially to INR 34.22 crore, accompanied by an improvement in basic EPS to INR 3.94.
Significant sequential expansion in revenue, PBT, and PAT demonstrated improved operating scale during the quarter.
05 · Items worth noticing
The line items that can distort a quick read
The company reported provisions amounting to INR 2.78 crore for the quarter ended September 30, 2026.
The company recorded provisions of INR 2.78 crore during the quarter.
Total tax expense for the quarter was reported at INR 9.23 crore against a PBT of INR 43.38 crore.
06 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations grew from INR 191.45 crore in Q1 FY27 to INR 240.46 crore in Q2 FY27.
PAT increased from INR 24.68 crore in Q1 FY27 to INR 34.22 crore in Q2 FY27.
Revenue from operations increased sequentially from INR 49.01 crore in Q1 FY27 to INR 240.46 crore in Q2 FY27.
07 · Key Q&A
The quarter, answered directly
What does Ind-Swift Laboratories do?
Ind-Swift Laboratories Limited operates in the pharmaceutical sector, focusing primarily on the research, development, and manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and finished dosage formulations. The company serves global pharmaceutical markets, supplying regulatory-compliant chemical entities and pharmaceutical ingredients.
What is the clearest takeaway from Q2 FY27?
Ind-Swift Laboratories Limited reported consolidated revenue from operations of INR 240.46 crore for the quarter ended September 30, 2026 (Q2 FY27), reflecting a sequential increase from INR 191.45 crore recorded in the preceding quarter (Q1 FY27). Total income for the quarter stood at INR 248.06 crore compared to INR 199.11 crore in Q1 FY27.
What drove revenue or demand?
Revenue from operations rose by 25.60% sequentially to INR 240.46 crore in Q2 FY27 from INR 191.45 crore in Q1 FY27, driven by higher operational output and sales volume.
What mattered most for margins or profitability?
PAT margin improved to 14.23% in Q2 FY27 from 12.89% in Q1 FY27, representing a sequential expansion of approximately 134 basis points.
What should the next disclosure help confirm?
Monitor subsequent quarterly filings to track whether the sequential revenue expansion above INR 240 crore is sustained.
08 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
09 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Sustained Revenue Trajectory: Monitor subsequent quarterly filings to track whether the sequential revenue expansion above INR 240 crore is sustained.
- 02
Margin Stability: Track future PAT margins and cost components, including finance costs and provisions, to evaluate operational consistency.
- 03
Subsequent Quarter Performance: Monitor upcoming quarterly disclosures to verify whether the scale achieved in Q2 FY27 is sustained across subsequent periods.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.